🇮🇳 India Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Ambalal Sarabhai Enterprises Limited AMBALALSA NSEPHARMA

Healthcare · Drug Manufacturers - Specialty & Generic · India
https://www.ase.life
Company Profile ↓
₹31.90
-4.35% 1Y
Mkt Cap₹244.46 Cr
P/E13.75
P/B1.52
52W High₹37.30
52W Low₹30.91
Book Value₹20.66
EPS (TTM)₹2.32

Company Overview

Ambalal Sarabhai Enterprises Limited, together with its subsidiaries, manufactures, markets, and supplies pharmaceutical products in India and internationally. The company offers products for oncology, infertility, and uro-gynaec areas; generic and veterinary products; antifungal active ingredient products; vitamin C coated products; and analytical, test, and measuring instruments, as well as supplies finished dosage forms and active pharmaceutical ingredients. It also provides broadcast and professional video/audio, and electronic products. Ambalal Sarabhai Enterprises Limited was incorporated in 1977 and is based in Ahmedabad, India.

Why Investors Should Care

Consistent Profit Growth

Net profit has compounded at 15.9% per year over the last five years.

Reasonable Valuation

Trades at a P/E of 13.8, below the sector median of 39.7.

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.36.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Mar 2026 Revenue of ₹200.99 Cr (+2.9% YoY); net profit ₹17.80 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +2.9%, earnings +261.1%.
  • 5-Year Trend Long-term compounding — revenue CAGR 5.8%, profit CAGR 15.9%.

Growth & Price Performance

Compounded Sales Growth

5 Years:5.82%
1 Year:2.91%

Compounded Profit Growth

5 Years:15.86%
1 Year:261.05%

Stock Price Performance

1 Year:-4.35%
6 Months:-
3 Months:-
1 Month:-3.97%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot
52-Week Range 15% of range
₹30.91 ₹37.30
Trend Signals
  • Price vs 50-DMABelow
  • RSI (14)46.32 · Neutral
Price Performance
1M-3.97%
1Y-4.35%
Valuation vs Sector

P/E of 13.75 is below the sector median of 39.70 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Profit CAGR of 15.9% over 5 years.
  • Generates positive free cash flow.

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
13.75
Industry PE
39.70
Forward P/E est.
6.88
PEG Ratio
-
Book Value
₹20.66
Price to Book
1.52
P/S
1.19
EV/EBITDA
10.29
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
5.82%
Profit 5Y
15.86%
Revenue (YoY)
2.91%
Earnings (YoY)
261.05%

Profitability & Returns

ROCE
12.35%
ROE
11.24%
ROA
6.33%
Profit Margin
8.86%
Op Margin
8.10%
Gross Margin
36.96%
EPS (Latest Qtr)
₹0.85
EPS (TTM)
₹2.32

Balance Sheet & Liquidity

Debt/Equity
0.36
Quick Ratio
1.04
Current Ratio
1.27
Debt
₹56.53 Cr
Total Assets
₹281.13 Cr
Current Assets
₹125.03 Cr
Working Capital
₹26.49 Cr

Ownership

Promoter Holding
35.07%
Chg in Prom Hold
-0.00%
FII / Inst Holding
0.00%
Chg in FII Hold
-0.34%

Financial Snapshot

Enterprise Value
₹244.46 Cr
Total Revenue (TTM)
₹200.99 Cr
EBITDA
₹26.50 Cr
Free Cash Flow
₹7.34 Cr
Operating Cash Flow
₹13.40 Cr
Shares Outstanding
₹7.66 Cr
Gross Margin
36.96%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 AMBALALSA Ambalal Sarabhai Enterprises Limited NSEPHARMA 31.90 13.75 ₹244.46 Cr 0.00% 12.35% 11.24% 5.82% 15.86%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,948.80 40.77 ₹4.68 L Cr 0.83% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 7,315.50 75.61 ₹1.94 L Cr 0.44% 18.96% 15.32% 11.27% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,952.20 87.70 ₹1.68 L Cr 0.78% 9.05% 25.79% 13.27% 20.22%
5 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 8,981.00 66.51 ₹1.29 L Cr 0.23% 19.79% 20.48% 15.33% 33.34%
6 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,440.10 22.07 ₹1.16 L Cr 0.90% 14.86% 11.27% 7.23% 11.45%
7 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,137.40 22.71 ₹1.14 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
8 LUPIN Lupin Limited NIFTY_MIDNSEPHARMA 2,494.30 21.42 ₹1.14 L Cr 0.72% 28.42% 23.76% 19.10% 131.46%
9 MAXHEALTH Max Healthcare Institute Limited NSEAIPHARMA 1,099.00 99.82 ₹1.07 L Cr 0.18% 12.57% 13.42% 22.37% 9.34%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue 44.44 Cr36.10 Cr40.01 Cr43.11 Cr54.35 Cr40.70 Cr44.70 Cr-64.81 Cr40.34 Cr44.45 Cr52.00 Cr65.49 Cr
Cost of Revenue --------40.93 Cr23.28 Cr25.78 Cr30.17 Cr39.92 Cr
Gross Profit --------23.89 Cr17.06 Cr18.67 Cr21.83 Cr25.56 Cr
Operating Expenses 41.09 Cr40.07 Cr39.00 Cr40.58 Cr49.70 Cr40.23 Cr42.16 Cr-19.49 Cr16.46 Cr19.22 Cr18.72 Cr20.91 Cr
Operating Income 2.43 Cr-5.02 Cr-13.00 L1.40 Cr4.40 Cr-51.00 L1.53 Cr-4.40 Cr59.95 L-54.64 L3.12 Cr4.65 Cr
EBITDA 3.35 Cr-3.97 Cr1.01 Cr2.53 Cr4.65 Cr47.00 L2.54 Cr--6.89 L9.82 Cr1.98 Cr6.02 Cr8.72 Cr
Interest Expense 99.00 L95.00 L92.00 L99.00 L90.00 L95.00 L1.22 Cr-95.84 L1.01 Cr96.14 L69.75 L1.42 Cr
Pretax Income 7.15 Cr-4.60 Cr1.80 Cr2.04 Cr8.29 Cr84.00 L3.11 Cr--2.05 Cr7.93 Cr-3.91 L4.36 Cr6.25 Cr
Tax Provision 1.44 Cr-27.00 L72.00 L69.99 L-72.04 L50.00 L49.01 L--1.78 Cr-28.97 L52.12 L71.98 L-24.81 L
Net Income 5.71 Cr-4.87 Cr1.08 Cr1.33 Cr9.02 Cr35.00 L2.62 Cr--26.76 L8.22 Cr-56.01 L3.06 Cr6.50 Cr
Diluted EPS 0.75-0.640.140.171.180.050.34--0.031.07-0.070.400.85

Profit & Loss (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue 124.00 Cr132.00 Cr134.00 Cr125.00 Cr150.00 Cr133.00 Cr163.00 Cr-169.63 Cr172.94 Cr195.31 Cr200.99 Cr
Cost of Revenue --------107.43 Cr108.76 Cr122.94 Cr126.71 Cr
Gross Profit --------62.21 Cr64.19 Cr72.37 Cr74.29 Cr
Operating Expenses 129.00 Cr145.00 Cr137.00 Cr137.00 Cr144.00 Cr136.00 Cr165.00 Cr-55.15 Cr58.95 Cr63.13 Cr58.01 Cr
Operating Income -9.00 Cr-30.00 Cr-7.00 Cr-14.00 Cr4.00 Cr-6.00 Cr-4.00 Cr-7.06 Cr5.24 Cr9.24 Cr16.28 Cr
EBITDA -4.00 Cr-13.00 Cr-3.00 Cr-12.00 Cr6.00 Cr-3.00 Cr-2.00 Cr-20.31 Cr15.92 Cr13.08 Cr26.50 Cr
Interest Expense 10.00 Cr4.00 Cr5.00 Cr3.00 Cr3.00 Cr4.00 Cr3.00 Cr-2.39 Cr5.69 Cr4.24 Cr4.05 Cr
Pretax Income -6.00 Cr62.00 Cr-14.00 Cr8.00 Cr8.00 Cr15.00 Cr33.00 Cr-15.17 Cr6.65 Cr4.83 Cr18.51 Cr
Tax Provision -78.00 L13.64 Cr-4.76 Cr6.72 Cr3.84 Cr90.00 L3.30 Cr-3.72 Cr97.03 L-9.81 L70.32 L
Net Income -7.00 Cr48.00 Cr-18.00 Cr1.00 Cr4.00 Cr14.00 Cr29.00 Cr-11.45 Cr5.68 Cr4.93 Cr17.80 Cr
Diluted EPS -0.876.28-2.380.170.551.833.836.161.490.740.642.32

Balance Sheet (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets 169.00 Cr180.00 Cr160.00 Cr197.00 Cr214.00 Cr186.00 Cr210.00 Cr-245.74 Cr249.52 Cr271.68 Cr281.13 Cr
Current Assets --------110.94 Cr118.54 Cr118.59 Cr125.03 Cr
Cash & Equivalents --------10.13 Cr10.75 Cr4.89 Cr6.19 Cr
Inventory --------17.43 Cr16.18 Cr23.63 Cr22.23 Cr
Receivables --------27.34 Cr26.26 Cr44.14 Cr47.71 Cr
Total Liabilities --------114.82 Cr113.10 Cr131.70 Cr122.77 Cr
Current Liabilities --------102.87 Cr102.32 Cr120.51 Cr98.54 Cr
Long Term Debt --------10.35 Cr9.06 Cr7.63 Cr17.65 Cr
Total Debt 46.00 Cr47.00 Cr42.00 Cr43.00 Cr40.00 Cr31.00 Cr28.00 Cr-45.20 Cr46.11 Cr50.89 Cr56.53 Cr
Total Equity -9.00 Cr39.00 Cr26.00 Cr27.00 Cr31.00 Cr45.00 Cr74.00 Cr-130.92 Cr136.42 Cr139.97 Cr158.36 Cr
Shares Outstanding --------7.66 Cr7.66 Cr7.66 Cr7.66 Cr

Cash Flows (Annual)

Figures in INR.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow -8.00 Cr-75.00 Cr5.00 Cr-7.00 Cr19.00 Cr-7.00 Cr-2.00 Cr-5.72 Cr8.89 Cr-17.62 Cr13.40 Cr
Investing Cash Flow 10.00 Cr80.00 Cr-3.00 Cr18.00 Cr-9.00 Cr17.00 Cr10.00 Cr--16.78 Cr-5.30 Cr13.26 Cr-10.25 Cr
Financing Cash Flow -1.00 Cr-3.00 Cr-6.00 Cr-2.00 Cr-6.00 Cr-14.00 Cr-6.00 Cr-9.09 Cr-2.95 Cr-1.52 Cr-1.85 Cr
Capital Expenditure 9.00 Cr87.00 Cr-4.00 Cr15.00 Cr-10.00 Cr-3.00 Cr9.00 Cr--20.67 Cr-2.91 Cr-2.72 Cr-6.06 Cr
Free Cash Flow 1.00 Cr12.00 Cr1.00 Cr8.00 Cr9.00 Cr-10.00 Cr7.00 Cr--14.94 Cr5.98 Cr-20.34 Cr7.34 Cr
Net Change in Cash 1.00 Cr2.00 Cr-4.00 Cr8.00 Cr3.00 Cr-4.00 Cr2.00 Cr--1.97 Cr64.63 L-5.88 Cr1.30 Cr

Ratios (Annual)

Figures in %.

Metric Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Margin % --------36.7%37.1%37.1%37.0%
Operating Margin % -7.3%-22.7%-5.2%-11.2%2.7%-4.5%-2.5%-4.2%3.0%4.7%8.1%
Net Margin % -5.6%36.4%-13.4%0.8%2.7%10.5%17.8%-6.7%3.3%2.5%8.9%
ROE % 77.8%123.1%-69.2%3.7%12.9%31.1%39.2%-8.7%4.2%3.5%11.2%
ROCE % --------4.9%3.6%6.1%8.9%

Shareholding Pattern

Insiders
35.07%
Institutions
0.00%
Public Float
0.00%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for AMBALALSA

Google News Mon, 20 Apr 2026

AMBALALSA Stock Price and Chart — NSE:AMBALALSA - TradingView

<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTE1XMmpqWktLeGR1d0ZFc0RodlFjNkFIeUdOTm5CZGxqSGVGSlZtUUtIM2U3Nlh1MTUtRWp2QURpT2JpeXFsQm10TEp2bExZNmx3c3VGNjQ3b2VNSUpqSEpZ?oc=5" target="_blank">AMBALALSA Stock Price and Chart — NSE:A…

Google News Mon, 04 Aug 2025

Ambalal Sarabhai Enterprises Ltd. Share Price Live Today - CNBC TV18

<a href="https://news.google.com/rss/articles/CBMilgFBVV95cUxNQ0Z6Njlibnh5VHVHWms3ZW1wcVFhSzQtYVdjWGdvSmxNTkdzTXR4MzFzS3FVcXNod25uQ3l1bnVlNGpnMmRXZFlVQlJILW84RzN2R3NrN3l6S2ZrQ2FtRTllOXhjc2ZyVDRLS0NOeURuNTlZN0NlWHk1TmJ2a3cwcHEwWm44R1I1NW5GOW…

Google News ue, 06 Jul 2021

ZENOTECH Stock Price and Chart — BSE:ZENOTECH - TradingView

<a href="https://news.google.com/rss/articles/CBMiXkFVX3lxTE5GdE5sMmw4YjFwdVZPSnhpRk5lRHlKVlpVMmk2SDhWMWpZY1FIUW9ORWVaalRKbmRKVE1McF9SbUc0M3dFMHpCSDFDbXlCOFpLaEZlMzFrWUEyTWtRM2c?oc=5" target="_blank">ZENOTECH Stock Price and Chart — BSE:ZEN…

AMBALALSA — Frequently Asked Questions

What is the current share price of Ambalal Sarabhai Enterprises Limited (AMBALALSA)?

As of 2026-07-16 05:21 IST, Ambalal Sarabhai Enterprises Limited (AMBALALSA) trades at ₹31.90 on NSE. Its 52-week range is ₹30.91 to ₹37.30.

What is the market capitalisation of AMBALALSA?

Ambalal Sarabhai Enterprises Limited (AMBALALSA) has a market capitalisation of ₹244.46 Cr on NSE.

What is the P/E ratio of AMBALALSA?

AMBALALSA trades at a trailing price-to-earnings (P/E) ratio of 13.75. The industry average P/E is 39.70. Its price-to-book (P/B) ratio is 1.52.

What is the return on equity (ROE) of AMBALALSA?

AMBALALSA has a return on equity (ROE) of 11.24%. Its return on capital employed (ROCE) is 12.35%.

Is AMBALALSA a good stock to buy?

This page provides a data-driven analysis of Ambalal Sarabhai Enterprises Limited (AMBALALSA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space